Download PDF
Thorac Cardiovasc Surg
DOI: 10.1055/a-2616-4962
Original Cardiovascular

Impact of SGLT2 Inhibitor Therapy on Patients Undergoing Cardiac Surgery

Zulfugar T. Taghiyev 
1   Department of Adult and Pediatric Cardiovascular Surgery, University Hospital Giessen, Giessen, Germany
,
Lili-Marie Beier
1   Department of Adult and Pediatric Cardiovascular Surgery, University Hospital Giessen, Giessen, Germany
,
Carina Leweling
1   Department of Adult and Pediatric Cardiovascular Surgery, University Hospital Giessen, Giessen, Germany
,
Sophia Gunkel
1   Department of Adult and Pediatric Cardiovascular Surgery, University Hospital Giessen, Giessen, Germany
,
Kevin Mike Sadowski
1   Department of Adult and Pediatric Cardiovascular Surgery, University Hospital Giessen, Giessen, Germany
,
Birgit Assmus
2   Department of Cardiology, University Hospital Giessen, Giessen, Hessen, Germany
,
Andreas Boening
1   Department of Adult and Pediatric Cardiovascular Surgery, University Hospital Giessen, Giessen, Germany
› Author Affiliations
Funding This research made use of data collected from the mesenteric ischemia registry, which was supported by the Clinician Scientist Program of Justus-Liebig-University (JLU-CAREER), funded by the German Research Council (DFG, GEPRIS project: 413584448).
› Further Information
   Permissions and Reprints All articles of this category

Abstract

Background

Sodium-glucose cotransporter-2 (SGLT2) inhibitors (SGLT2i) are nephroprotective in patients with recompensated acute and chronic heart failure (HF) and chronic kidney disease, but their potential influence during cardiac surgery is unclear. Currently, discontinuation of SGLT2i at least 2 days before surgery is recommended.

Methods

Between March 2022 and December 2023, 53 cardiac surgical patients on SGLT2i therapy in addition to standard medical treatment for HF were compared with 447 other HF patients from the same period. After 1:1 covariate adjustment, 33 patients with SGLT2i treatment were matched with 33 controls. The primary endpoint was a change in estimated glomerular filtration rate (eGFR) 36 hours after surgery. Secondary endpoints were changes in eGFR, cumulative urine output, diuretic efficacy, and albuminuria over seven postoperative days.

Results

Mean baseline eGFR was similar between the groups (p = 0.973). Thirty-six hours postoperatively, eGFR was significantly higher in the SGLT2i group by a mean difference (MD) of 11.8 mL/min (95% CI [3.12–20.44]; p = 0.009) compared with the control group. The mean urinary albumin level was 18.1 mg/mL lower in the SGLT2i group (95% CI [−42.5–6.33]; p = 0.143). There were numerically positive changes in urine output and diuretic efficacy in the SGLT2i group without significant difference: MD 131.4 mL/24 hours (95% CI [−366.7–629.5]; p = 0.600) and MD 11.3 mL/mg (95% CI [−12.2–34.7]; p = 0.301), respectively, although the dosage of diuretics was higher in controls (30.6 ± 43.7 vs. 51.3 ± 130.1 mg/24 hours; p = 0.268, respectively).

Conclusion

SGLT2i may have nephroprotective effects in patients undergoing heart surgery with extracorporeal circulation. More evidence is needed to determine whether SGTL2i needs to be discontinued before surgery.

Keywords

SGLT2i - renal failure - kidney injury - cardiac surgery

Note

The manuscript was presented as a talk at the DGK Annual Meeting in Hamburg, Germany, on September 27, 2024.


Data Availability Statement

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.


Authors' Contributions

Z.T.T contributed to conceptualization; data collection and curation; investigation; methodology; supervision; validation; visualization; formal analysis; writing—original draft. L-M.B., C.L., M.S. and S.G. contributed to data collection, validation, and curation. B.A. contributed to supervision; conceptualization; writing—review and editing. A.B. contributed to administration; supervision; data curation and validation; review, and editing.




Publication History

Received: 04 March 2025

Accepted: 19 May 2025

Accepted Manuscript online:
20 May 2025

Article published online:
05 June 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • References

  • 1 Vives M, Wijeysundera D, Marczin N, Monedero P, Rao V. Cardiac surgery-associated acute kidney injury. Interact Cardiovasc Thorac Surg 2014; 18 (05) 637-645
    PubMedSearch in Google Scholar
  • 2 Kellum JA, Lameire N. KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care 2013; 17 (01) 204
    CrossrefPubMedSearch in Google Scholar
  • 3 Mao H, Katz N, Ariyanon W. et al. Cardiac surgery-associated acute kidney injury. Cardiorenal Med 2013; 3 (03) 178-199
    PubMedSearch in Google Scholar
  • 4 Wang Z, Xu J, Zhang Y. et al. Prediction of acute kidney injury incidence following acute type A aortic dissection surgery with novel biomarkers: a prospective observational study. BMC Med 2023; 21 (01) 503
    PubMedSearch in Google Scholar
  • 5 Rosner MH, Okusa MD. Acute kidney injury associated with cardiac surgery. Clin J Am Soc Nephrol 2006; 1 (01) 19-32
    PubMedSearch in Google Scholar
  • 6 Haase M, Müller C, Damman K. et al. Pathogenesis of cardiorenal syndrome type 1 in acute decompensated heart failure: workgroup statements from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol 2013; 182: 99-116
    CrossrefPubMedSearch in Google Scholar
  • 7 O'Neal JB, Shaw AD, Billings IV FT. Acute kidney injury following cardiac surgery: current understanding and future directions. Crit Care 2016; 20 (01) 187
    CrossrefPubMedSearch in Google Scholar
  • 8 Choi MR, Kouyoumdzian NM, Rukavina Mikusic NL. et al. Renal dopaminergic system: Pathophysiological implications and clinical perspectives. World J Nephrol 2015; 4 (02) 196-212
    PubMedSearch in Google Scholar
  • 9 Patel NN, Rogers CA, Angelini GD, Murphy GJ. Pharmacological therapies for the prevention of acute kidney injury following cardiac surgery: A systematic review. Heart Fail Rev 2011; 16 (06) 553-567
    PubMedSearch in Google Scholar
  • 10 Carcoana OV, Mathew JP, Davis E. et al. Mannitol and dopamine in patients undergoing cardiopulmonary bypass: A randomized clinical trial. Anesth Analg 2003; 97 (05) 1222-1229
    PubMedSearch in Google Scholar
  • 11 Dehne MG, Klein TF, Mühling J, Sablotzki A, Osmer C, Hempelmann G. Impairment of renal function after cardiopulmonary bypass is not influenced by dopexamine. Ren Fail 2001; 23 (02) 217-230
    PubMedSearch in Google Scholar
  • 12 Lassnigg A, Donner E, Grubhofer G, Presterl E, Druml W, Hiesmayr M. Lack of renoprotective effects of dopamine and furosemide during cardiac surgery. J Am Soc Nephrol 2000; 11 (01) 97-104
    CrossrefPubMedSearch in Google Scholar
  • 13 Sumeray M, Robertson C, Lapsley M, Bomanji J, Norman AG, Woolfson RG. Low dose dopamine infusion reduces renal tubular injury following cardiopulmonary bypass surgery. J Nephrol 2001; 14 (05) 397-402
    PubMedSearch in Google Scholar
  • 14 Woo EB, Tang AT, el-Gamel A. et al. Dopamine therapy for patients at risk of renal dysfunction following cardiac surgery: Science or fiction?. Eur J Cardiothorac Surg 2002; 22 (01) 106-111
    PubMedSearch in Google Scholar
  • 15 Yavuz S, Ayabakan N, Dilek K, Ozdemir A. Renal dose dopamine in open heart surgery. Does it protect renal tubular function?. J Cardiovasc Surg (Torino) 2002; 43 (01) 25-30
    PubMedSearch in Google Scholar
  • 16 Yavuz S, Ayabakan N, Goncu MT, Ozdemir IA. Effect of combined dopamine and diltiazem on renal function after cardiac surgery. Med Sci Monit 2002; 8: PI45-PI50 Ann Thorac Surg. 2023;115:34–42
    PubMedSearch in Google Scholar
  • 17 Brown JR, Baker RA, Shore-Lesserson L. et al. The Society of Thoracic Surgeons/Society of Cardiovascular Anesthesiologists/American Society for Extracorporeal Technology Clinical Practice Guidelines for the Prevention of Adult Cardiac Surgery-Associated Acute Kidney Injury. Anesth Analg 2023; 136 (01) 176-184
    PubMedSearch in Google Scholar
  • 18 Dumann E, Menne J. SGLT2-inhibitors: What is new? [in German.]. Nephrologe 2021; 16 (04) 241-255
    CrossrefPubMedSearch in Google Scholar
  • 19 Wheeler DC, Stefánsson BV, Jongs N. et al.; DAPA-CKD Trial Committees and Investigators. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol 2021; 9 (01) 22-31
    CrossrefPubMedSearch in Google Scholar
  • 20 Packer M. Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling/autophagy hypothesis. Circulation 2022; 146 (18) 1383-1405
    PubMedSearch in Google Scholar
  • 21 Hallow KM, Helmlinger G, Greasley PJ, McMurray JJV, Boulton DW. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab 2018; 20 (03) 479-487
    PubMedSearch in Google Scholar
  • 22 Seferović PM, Petrie MC, Filippatos GS. et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2018; 20 (05) 853-872
    CrossrefPubMedSearch in Google Scholar
  • 23 Murton M, Goff-Leggett D, Bobrowska A. et al. Burden of chronic kidney disease by KDIGO categories of glomerular filtration rate and albuminuria: A systematic review. Adv Ther 2021; 38 (01) 180-200
    PubMedSearch in Google Scholar
  • 24 Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron J 1976; 16 (01) 31-41
    CrossrefPubMedSearch in Google Scholar
  • 25 Piperidou A, Sarafidis P, Boutou A. et al. The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. J Hypertens 2019; 37 (07) 1334-1343
    PubMedSearch in Google Scholar
  • 26 Böhm M, Bauersachs J. Sodium-glukose-transporter 2-Hemmer bei herzinsuffizienz mit erhaltener auswurffraktion. Kardiologie 2023; 17: 116-122
    PubMedSearch in Google Scholar
  • 27 Kosiborod MN, Jhund PS, Docherty KF. et al. Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: Results from the DAPA-HF trial. Circulation 2020; 141 (02) 90-99
    PubMedSearch in Google Scholar
  • 28 Serenelli M, Böhm M, Inzucchi SE. et al. Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). Eur Heart J 2020; 41 (36) 3402-3418
    PubMedSearch in Google Scholar
  • 29 Wanner C, Inzucchi SE, Lachin JM. et al.; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375 (04) 323-334
    PubMedSearch in Google Scholar
  • 30 Beldhuis IEP, Lam CSP, Testani JM. et al. Evidence-based medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease. Circulation 2022; 145 (09) 693-712
    CrossrefPubMedSearch in Google Scholar
  • 31 Snel LIP, Oosterom-Eijmael MJP, Rampanelli E. et al. The effects of sodium-glucose transporter 2 inhibition on cardiac surgery-associated acute kidney injury: An open-label randomized pilot study. J Clin Anesth 2025; 103: 111811
    PubMedSearch in Google Scholar
  • 32 Buse JB, Wexler DJ, Tsapas A. et al. 2019 Update to: Management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2020; 43 (02) 487-493 Erratum in: Diabetes Care. 2020 Jul;43(7):1670. PMID: 31857443; PMCID: PMC6971782
    CrossrefPubMedSearch in Google Scholar
  • 33 McDonagh TA, Metra M, Adamo M. et al.; ESC Scientific Document Group. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2023; 44 (37) 3627-3639 Erratum in: Eur Heart J. 2024 Jan 1;45(1):53. PMID: 37622666
    PubMedSearch in Google Scholar
  • 34 Petrie MC, Verma S, Docherty KF. et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA 2020; 323 (14) 1353-1368
    PubMedSearch in Google Scholar